The ASX slipped as Wall Street’s tech wobble pushed markets into risk-off mode, dragging miners, gold stocks and tech lower.
Some of our most promising biotechs have taken part in a pre yuletide rush of clinical trial updates – and there is much to cheer about.
Aurora Labs’ propulsion push has moved into a new league, putting a small Australian tech company on Europe’s defence-industry stage.
Loyal Metals’ second hole has struck a previously unknown zone of copper-rich mineralisation at its Highway Reward project.
Moonlight Resources wastes little time after listing, with drilling now underway at its Clermont gold project.
